Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,078
archived clinical trials in
Major Depression Disorder (MDD)

Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Comprehensive Psychiatric Care
mi
from
Pittsburgh, PA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Comprehensive Psychiatric Care
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Insite Clinical Research
mi
from
Pittsburgh, PA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Insite Clinical Research
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Bioscience Research, Llc
mi
from
Pittsburgh, PA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Bioscience Research, Llc
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Lincoln Research
mi
from
Lincoln, RI
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Lincoln Research
mi
from
Lincoln, RI
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Carolina Clinical Research Services
mi
from
Columbia, SC
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Carolina Clinical Research Services
mi
from
Columbia, SC
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Psychiatric Consultants
mi
from
Franklin, TN
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Psychiatric Consultants
mi
from
Franklin, TN
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Clinical NeuroScience Solutions, Inc.
mi
from
Memphis, TN
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Clinical NeuroScience Solutions, Inc.
mi
from
Memphis, TN
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Community Clinical Research
mi
from
Austin, TX
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Community Clinical Research
mi
from
Austin, TX
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
FutureSearch Trials of Dallas
mi
from
Dallas, TX
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
FutureSearch Trials of Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Ut Health-Houston
mi
from
Houston, TX
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Ut Health-Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Baylor College of Medicine
mi
from
Houston, TX
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Red Oak Psychiatry Associates, PA
mi
from
Houston, TX
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Red Oak Psychiatry Associates, PA
mi
from
Houston, TX
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
San Antonio Psychiatric Research Center
mi
from
San Antonio, TX
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
San Antonio Psychiatric Research Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Grayline Clinical Drug Trials
mi
from
Wichita Falls, TX
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Grayline Clinical Drug Trials
mi
from
Wichita Falls, TX
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Ericksen Research And Development
mi
from
Clinton, UT
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Ericksen Research And Development
mi
from
Clinton, UT
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Radiant Research, Inc.
mi
from
Murray, UT
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Radiant Research, Inc.
mi
from
Murray, UT
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Psychiatric And Behavioral Solutions
mi
from
Salt Lake City, UT
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Psychiatric And Behavioral Solutions
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Lifetree Clinical Research
mi
from
Salt Lake City, UT
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Lifetree Clinical Research
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Neuropsychiatric Associates
mi
from
Woodstock, VT
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Neuropsychiatric Associates
mi
from
Woodstock, VT
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Summit Research Network (Seattle) LLC
mi
from
Seattle, WA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Summit Research Network (Seattle) LLC
mi
from
Seattle, WA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Northbrooke Research Center
mi
from
Brown Deer, WI
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Northbrooke Research Center
mi
from
Brown Deer, WI
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Dean Foundation For Health Research & Education
mi
from
Middleton, WI
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Dean Foundation For Health Research & Education
mi
from
Middleton, WI
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Independent Psychiatric Consultants, Sc, Dba, Ipc Research
mi
from
Waukesha, WI
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Independent Psychiatric Consultants, Sc, Dba, Ipc Research
mi
from
Waukesha, WI
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Pacific Clinical Research Medical Group
mi
from
Arcadia, CA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Pacific Clinical Research Medical Group
mi
from
Arcadia, CA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Pharmacology Research Institute
mi
from
Encino, CA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Pharmacology Research Institute
mi
from
Encino, CA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Pharmacology Research Institute
mi
from
Los Alamitos, CA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Pharmacology Research Institute
mi
from
Los Alamitos, CA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Neuropsychiatric Research Center for Orange County
mi
from
Orange, CA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Neuropsychiatric Research Center for Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Anderson Clinical Research
mi
from
Redlands, CA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Anderson Clinical Research
mi
from
Redlands, CA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
California Neuroscience Research Medical Group, Inc
mi
from
Sherman Oaks, CA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
California Neuroscience Research Medical Group, Inc
mi
from
Sherman Oaks, CA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Schuster Medical Research Institute
mi
from
Sherman Oaks, CA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Schuster Medical Research Institute
mi
from
Sherman Oaks, CA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Pacific Clinical Research Medical Group
mi
from
Upland, CA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Pacific Clinical Research Medical Group
mi
from
Upland, CA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Connecticut Clinical Research
mi
from
Cromwell, CT
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Connecticut Clinical Research
mi
from
Cromwell, CT
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Meridien Research
mi
from
Brooksville, FL
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Meridien Research
mi
from
Brooksville, FL
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Comprehensive Clinical Development, Inc.
mi
from
Saint Petersburg, FL
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Comprehensive Clinical Development, Inc.
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Loyola University Medical Center
mi
from
Maywood, IL
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Clinco, Inc.
mi
from
Terre Haute, IN
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Clinco, Inc.
mi
from
Terre Haute, IN
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Comprehensive Clinical Development
mi
from
Jamaica, NY
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Comprehensive Clinical Development
mi
from
Jamaica, NY
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
FutureSearch Trials
mi
from
Austin, TX
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
FutureSearch Trials
mi
from
Austin, TX
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Northwest Clinical Research Center
mi
from
Bellevue, WA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Northwest Clinical Research Center
mi
from
Bellevue, WA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Local Institution
mi
from
Caba,
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Local Institution
mi
from
Caba,
Click here to add this to my saved trials
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients With Treatment Resistant Major Depression (TRD).
Status: Enrolling
Updated:  9/23/2015
Birmingham Psychiatry Pharmaceutical Studies, Inc.
mi
from
Birmingham, AL
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients With Treatment Resistant Major Depression (TRD).
Status: Enrolling
Updated: 9/23/2015
Birmingham Psychiatry Pharmaceutical Studies, Inc.
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients With Treatment Resistant Major Depression (TRD).
Status: Enrolling
Updated:  9/23/2015
Arkansas Psychiatric Clinic Clinical Research Trials, P.A.
mi
from
Little Rock, AR
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients With Treatment Resistant Major Depression (TRD).
Status: Enrolling
Updated: 9/23/2015
Arkansas Psychiatric Clinic Clinical Research Trials, P.A.
mi
from
Little Rock, AR
Click here to add this to my saved trials
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients With Treatment Resistant Major Depression (TRD).
Status: Enrolling
Updated:  9/23/2015
Catalina Research Institute
mi
from
Chino, CA
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients With Treatment Resistant Major Depression (TRD).
Status: Enrolling
Updated: 9/23/2015
Catalina Research Institute
mi
from
Chino, CA
Click here to add this to my saved trials
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients With Treatment Resistant Major Depression (TRD).
Status: Enrolling
Updated:  9/23/2015
Behavioral Research Specialists, LLC
mi
from
Glendale, CA
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients With Treatment Resistant Major Depression (TRD).
Status: Enrolling
Updated: 9/23/2015
Behavioral Research Specialists, LLC
mi
from
Glendale, CA
Click here to add this to my saved trials
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients With Treatment Resistant Major Depression (TRD).
Status: Enrolling
Updated:  9/23/2015
Pacific Clinical Research Medical Group
mi
from
Orange, CA
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients With Treatment Resistant Major Depression (TRD).
Status: Enrolling
Updated: 9/23/2015
Pacific Clinical Research Medical Group
mi
from
Orange, CA
Click here to add this to my saved trials
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients With Treatment Resistant Major Depression (TRD).
Status: Enrolling
Updated:  9/23/2015
Sharp Mesa Vista Hospital
mi
from
San Diego, CA
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients With Treatment Resistant Major Depression (TRD).
Status: Enrolling
Updated: 9/23/2015
Sharp Mesa Vista Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients With Treatment Resistant Major Depression (TRD).
Status: Enrolling
Updated:  9/23/2015
Artemis Institute for Clinical Research
mi
from
San Diego, CA
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients With Treatment Resistant Major Depression (TRD).
Status: Enrolling
Updated: 9/23/2015
Artemis Institute for Clinical Research
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients With Treatment Resistant Major Depression (TRD).
Status: Enrolling
Updated:  9/23/2015
Affiliated Research Institute
mi
from
San Diego, CA
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients With Treatment Resistant Major Depression (TRD).
Status: Enrolling
Updated: 9/23/2015
Affiliated Research Institute
mi
from
San Diego, CA
Click here to add this to my saved trials